Dimensional Fund Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Dimensional Fund Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.3M	Sell	1,361,884 -1,356,897	-50%	-$12.8M	﹤0.01%	2228
2026 Q2	$27.2M	Buy	2,718,781 +28,130	+1%	+$254K	﹤0.01%	1903
2026 Q1	$25.6M	Buy	2,690,651 +1,461,799	+119%	+$11.4M	0.01%	1854
2025 Q4	$9.6M	Buy	+1,228,852	New	+$8.88M	﹤0.01%	2297
2014 Q3	–	Sell	-3,679	Closed	-$47K	–	3546
2014 Q2	$47K	Buy	3,679 +3,300	+871%	+$32.1K	﹤0.01%	3439
2014 Q1	$4K	Hold	379	–	–	﹤0.01%	3577
2013 Q4	$3K	Hold	379	–	–	﹤0.01%	3524
2013 Q3	$3K	Sell	379 -44,626	-99%	-$226K	﹤0.01%	3556
2013 Q2	$70K	Buy	+45,005	New	+$77.6K	﹤0.01%	3413

Other funds holding BCRX

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

OP Asset Management Helsinki $11.8B AUM 34.59% 1-Year Est. Return

IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors's BCRX Position: Q3 2026 in Review

Dimensional Fund Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 50% in Q3 2026, selling an estimated $12.8M and leaving 1,361,884 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2228.

Dimensional Fund Advisors first reported a position in BCRX in Q2 2013 and has held it in 9 quarters since. The position peaked at $27.2M in Q2 2026. 116 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

Dimensional Fund Advisors held 1,361,884 shares of BioCryst Pharmaceuticals worth $11.3M as of Q3 2026.
Dimensional Fund Advisors sold 1,356,897 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $12.8M.
BioCryst Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2228 holding.
Dimensional Fund Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
Dimensional Fund Advisors's BioCryst Pharmaceuticals position peaked at $27.2M in Q2 2026.
116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.